Literature DB >> 29948850

Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients.

Phimpha Paboriboune1, Thomas Vial2, Philavanh Sitbounlang1, Stéphane Bertani2, Christian Trépo3, Paul Dény3,4, Francois-Xavier Babin5, Nicolas Steenkeste5, Pascal Pineau6, Eric Deharo7.   

Abstract

Hepatitis C virus (HCV) is a global health concern, notably in Southeast Asia, and in Laos the presentation of the HCV-induced liver disease is poorly known. Our objective was thus to describe a comprehensive HCV infection pattern in order to guide national health policies. A study on a group of 1765 patients formerly diagnosed by rapid test in health centres was conducted at the Centre of Infectiology Lao Christophe Merieux in Vientiane. The demographic information of patients, their infection status (viral load: VL), liver function (aminotransferases) and treatments were analysed. Results showed that gender distribution of infected people was balanced; with median ages of 53.8 for men and 51.6 years for women (13-86 years). The majority of patients (72%) were confirmed positive (VL > 50 IU/mL) and 28% of them had high VL (> 6log10). About 23% of patients had level of aminotransferases indicative of liver damage (> 40 IU/mL); but less than 20% of patients received treatment. Patients rarely received a second sampling or medical imaging. The survey also showed that cycloferon, pegylated interferon and ribavirin were the drugs prescribed preferentially by the medical staff, without following any international recommendations schemes. In conclusion, we recommend that a population screening policy and better management of patients should be urgently implemented in the country, respecting official guidelines. However, the cost of biological analysis and treatment are significant barriers that must be removed. Public health resolutions should be immediately enforced in the perspective of meeting the WHO HCV elimination deadline by 2030.

Entities:  

Keywords:  Antiviral agents; HCV incidence; Hepatitis C virus (HCV); Laos

Mesh:

Substances:

Year:  2018        PMID: 29948850      PMCID: PMC6178102          DOI: 10.1007/s12250-018-0039-9

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  26 in total

1.  Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A population-based cohort study (JPHC Study).

Authors:  Seiji Ishiguro; Manami Inoue; Yasuhito Tanaka; Masashi Mizokami; Motoki Iwasaki; Shoichiro Tsugane
Journal:  Cancer Lett       Date:  2010-10-29       Impact factor: 8.679

Review 2.  Prevention of hepatocellular carcinoma.

Authors:  Antonio Craxì; Calogero Cammà
Journal:  Clin Liver Dis       Date:  2005-05       Impact factor: 6.126

3.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

4.  HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis.

Authors:  Mei-Hsuan Lee; Tiffany I Hsiao; Shreenidhi R Subramaniam; An K Le; Vinh D Vu; Huy N Trinh; Jian Zhang; Mingjuan Jin; Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Mindie H Nguyen
Journal:  Am J Gastroenterol       Date:  2017-04-25       Impact factor: 10.864

5.  Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population.

Authors:  L Fanning; E Kenny; M Sheehan; B Cannon; M Whelton; J O'Connell; J K Collins; F Shanahan
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

6.  Dynamic coinfection with multiple viral subtypes in acute hepatitis C.

Authors:  Jennifer A Smith; Judith H Aberle; Vicki M Fleming; Peter Ferenci; Emma C Thomson; Peter Karayiannis; Angela R McLean; Heidemarie Holzmann; Paul Klenerman
Journal:  J Infect Dis       Date:  2010-11-10       Impact factor: 5.226

7.  Seroprevalence of hepatitis B and C virus infections among Lao blood donors.

Authors:  Prapan Jutavijittum; Amnat Yousukh; Bounthome Samountry; Khamtim Samountry; Angkham Ounavong; Te Thammavong; Jerapha Keokhamphue; Kan Toriyama
Journal:  Southeast Asian J Trop Med Public Health       Date:  2007-07       Impact factor: 0.267

8.  Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection.

Authors:  Emanuele Durante-Mangoni; Luca Vallefuoco; Rosanna Sorrentino; Domenico Iossa; Enzo Perna; Rosa Molaro; Umberto Braschi; Rosa Zampino; Giuseppe Sodano; Luigi Elio Adinolfi; Riccardo Utili; Giuseppe Portella
Journal:  J Med Virol       Date:  2013-07-29       Impact factor: 2.327

9.  [Immunomodulators in the "gold standard" of the chronic viral hepatitis C therapy].

Authors:  M G Romantsov; S N Kovalenko; T V Sologub; O V Anikina
Journal:  Antibiot Khimioter       Date:  2008

10.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.

Authors:  Jeffrey D Stanaway; Abraham D Flaxman; Mohsen Naghavi; Christina Fitzmaurice; Theo Vos; Ibrahim Abubakar; Laith J Abu-Raddad; Reza Assadi; Neeraj Bhala; Benjamin Cowie; Mohammad H Forouzanfour; Justina Groeger; Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Spencer L James; Jennifer MacLachlan; Reza Malekzadeh; Natasha K Martin; Ali A Mokdad; Ali H Mokdad; Christopher J L Murray; Dietrich Plass; Saleem Rana; David B Rein; Jan Hendrik Richardus; Juan Sanabria; Mete Saylan; Saeid Shahraz; Samuel So; Vasiliy V Vlassov; Elisabete Weiderpass; Steven T Wiersma; Mustafa Younis; Chuanhua Yu; Maysaa El Sayed Zaki; Graham S Cooke
Journal:  Lancet       Date:  2016-07-07       Impact factor: 79.321

View more
  1 in total

1.  Hepatitis C Virus NS2 Protein Suppresses RNA Interference in Cells.

Authors:  Hui Zhou; Qi Qian; Ting Shu; Jiuyue Xu; Jing Kong; Jingfang Mu; Yang Qiu; Xi Zhou
Journal:  Virol Sin       Date:  2019-11-27       Impact factor: 4.327

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.